Jazz Pharmaceuticals (JAZZ) Receives Average Recommendation of “Buy” from Brokerages

Jazz Pharmaceuticals (NASDAQ:JAZZ) has been assigned a consensus recommendation of “Buy” from the twenty-five analysts that are presently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $181.95.

JAZZ has been the subject of a number of research analyst reports. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $128.58 to $163.75 in a research report on Monday, March 19th. Bank of America upped their target price on Jazz Pharmaceuticals from $164.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, February 20th. BidaskClub upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, March 13th. Piper Jaffray Companies restated a “buy” rating and issued a $201.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, March 1st. Finally, HC Wainwright restated a “neutral” rating and issued a $160.00 target price (up from $150.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 23rd.

Jazz Pharmaceuticals traded up $1.04, reaching $167.09, on Tuesday, MarketBeat Ratings reports. The company’s stock had a trading volume of 364,894 shares, compared to its average volume of 460,556. Jazz Pharmaceuticals has a 52 week low of $128.58 and a 52 week high of $168.64. The firm has a market capitalization of $10.05 billion, a price-to-earnings ratio of 17.48, a price-to-earnings-growth ratio of 0.86 and a beta of 0.97. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.00 and a quick ratio of 2.88.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.73 by ($0.15). Jazz Pharmaceuticals had a return on equity of 23.78% and a net margin of 26.51%. The business had revenue of $436.40 million during the quarter, compared to the consensus estimate of $440.91 million. equities analysts anticipate that Jazz Pharmaceuticals will post 11.65 EPS for the current fiscal year.

In other news, EVP Michael Patrick Miller sold 200 shares of the stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $151.12, for a total transaction of $30,224.00. Following the completion of the sale, the executive vice president now owns 27,681 shares in the company, valued at approximately $4,183,152.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Matthew P. Young sold 1,420 shares of the stock in a transaction on Tuesday, May 15th. The shares were sold at an average price of $164.64, for a total value of $233,788.80. Following the sale, the chief financial officer now owns 37,623 shares of the company’s stock, valued at approximately $6,194,250.72. The disclosure for this sale can be found here. Insiders have sold a total of 20,837 shares of company stock valued at $3,200,686 in the last quarter. Insiders own 4.30% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Gateway Investment Advisers LLC lifted its holdings in shares of Jazz Pharmaceuticals by 70.0% in the fourth quarter. Gateway Investment Advisers LLC now owns 54,024 shares of the specialty pharmaceutical company’s stock valued at $7,274,000 after purchasing an additional 22,253 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 5.0% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 206,950 shares of the specialty pharmaceutical company’s stock valued at $27,866,000 after purchasing an additional 9,856 shares in the last quarter. Hamilton Lane Advisors LLC purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at $778,000. Acadian Asset Management LLC lifted its holdings in shares of Jazz Pharmaceuticals by 36,172.9% in the fourth quarter. Acadian Asset Management LLC now owns 17,411 shares of the specialty pharmaceutical company’s stock valued at $2,343,000 after purchasing an additional 17,363 shares in the last quarter. Finally, Rice Hall James & Associates LLC lifted its holdings in shares of Jazz Pharmaceuticals by 70.5% in the fourth quarter. Rice Hall James & Associates LLC now owns 31,467 shares of the specialty pharmaceutical company’s stock valued at $4,237,000 after purchasing an additional 13,008 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply